FDA approves new dosing schedule for Lilly's Alzheimer's drug Kisunla

Eli Lilly has secured FDA approval for a label update to its Alzheimer's treatment, Kisunla (donanemab-azbt), introducing a new titration dosing schedule that significantly reduces the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) by 41% at 24 weeks and 35% at 52 weeks, while maintaining comparable amyloid plaque removal. This safety enhancement bolsters the profile of the recently approved drug. The update comes as Lilly demonstrates robust financial health, with 36% revenue growth, an 81.7% gross profit margin, and strong anticipated Q2 earnings driven by its weight loss and diabetes medications, Mounjaro and Zepbound, alongside strategic moves like the acquisition of Verve Therapeutics.

Analysis

Eli Lilly has significantly de-risked its Alzheimer's treatment, Kisunla (donanemab-azbt), by securing FDA approval for a modified titration dosing schedule. This new regimen reduces the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) by a notable 41% at 24 weeks and 35% at 52 weeks, a critical safety enhancement that does not compromise efficacy, as amyloid plaque reduction remains comparable to the original dosing. This regulatory win complements the company's robust financial health, characterized by 36% revenue growth over the last twelve months and an industry-leading gross profit margin of 81.7%. The positive outlook is further reinforced by strong analyst forecasts for the upcoming second-quarter earnings, with JPMorgan projecting sales of $14.8 billion—$370 million above consensus—driven by the high-performing weight loss and diabetes drugs Mounjaro and Zepbound. Eli Lilly's growth strategy is also evident in its recent corporate actions, including a definitive agreement to acquire Verve Therapeutics for up to $1.3 billion and the declaration of a $1.50 per share quarterly dividend, signaling both a commitment to pipeline expansion and shareholder returns.

Key Decisions for Investors

• The FDA approval of a safer dosing schedule for Kisunla improves its commercial viability and competitive positioning in the Alzheimer's market, warranting an upward revision of the drug's potential peak sales estimates.
• Investors should monitor the upcoming Q2 earnings report for confirmation of the strong sales trajectories for Mounjaro and Zepbound, which remain the primary drivers of the company's near-term growth and ability to outperform consensus estimates.
• The acquisition of Verve Therapeutics and positive data for other pipeline assets like bimagrumab underscore a long-term strategy to dominate high-growth therapeutic areas, suggesting that the current valuation is supported by a multi-faceted growth narrative beyond its current blockbusters.
• Given the combination of positive regulatory news, strong fundamentals, and strategic M&A, maintaining a bullish stance may be justified, with the recently declared dividend providing an additional element of return for long-term holders.